<DOC>
	<DOCNO>NCT00829010</DOCNO>
	<brief_summary>The purpose study : - To evaluate immunogenicity , safety reactogenicity pneumococcal vaccine GSK1024850A HIV infect infant , HIV expose uninfected infant HIV unexposed uninfected infant follow 3-dose primary vaccination 6 , 10 14 week age follow booster vaccination 9-10 month age . - To evaluate immunogenicity , safety reactogenicity pneumococcal vaccine GSK1024850A HIV unexposed uninfected infant receive either 3-dose primary vaccination accord EPI vaccination schedule 6 , 10 14 week age without booster vaccination 9-10 month age 2-dose primary vaccination 6 14 week age follow booster vaccination 9-10 month age . - This study also aim assess impact pneumococcal vaccine GSK1024850A nasopharyngeal carriage S. pneumoniae H. influenzae 24 month age study participant .</brief_summary>
	<brief_title>Primary Booster Vaccination Study With Pneumococcal Vaccine HIV Infected , HIV Exposed Uninfected HIV Uninfected Children 6 10 Weeks Age .</brief_title>
	<detailed_description>This protocol posting update accord Protocol amendment 1 , December 08</detailed_description>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female subject , include 610 week age time first vaccination . Subjects investigator believe parent ( ) /guardian ( ) comply requirement protocol . Written inform consent obtain parent ( ) /guardian ( ) child/ward . Free know suspected health problem ( establish medical history clinical examination enter study ) . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . A family history hereditary immunodeficiency HIV infection . Major congenital defect serious chronic illness HIV infection . For HIV infect infant : Moderately severely symptomatic : stage III IV accord late version WHO classification . Administration immunoglobulins and/or blood product since birth plan administration study period . Previous vaccination diphtheria , tetanus , pertussis , hepatitis B , Haemophilus influenzae type b , and/or Streptococcus pneumoniae . History , intercurrent , diphtheria , tetanus , pertussis , Haemophilus influenzae type b disease . History allergic disease reaction likely exacerbate component vaccine . History neurological disorder seizure . Acute disease time enrolment . Babies weight age &lt; 3rd percentile Visit 1 , use standard growth chart , exception HIV infect infant decision enrolment leave investigator 's discretion . Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation gastrointestinal ( GI ) tract , intussusception ( IS ) medical condition determine serious investigator . Gastroenteritis within 7 day precede study vaccine administration ( warrant deferral vaccination ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>10 Weeks</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Booster vaccination</keyword>
	<keyword>Safety</keyword>
	<keyword>Primary vaccination</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Pneumococcal disease</keyword>
</DOC>